Novel radiometal-binding compounds for the diagnosis or treatment of prostate-specific membrane antigen-expressing cancers - Patents.com
Novel PSMA-targeting compounds with modulated albumin and PSMA binding enhance tumor uptake and retention, addressing supply limitations and efficacy challenges of Lu-PSMA-617, achieving higher radiation doses and improved therapeutic outcomes in prostate cancer treatment.
Patent Information
- Application Number
- JP2023081323
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-10-22
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2038-10-22
AI Technical Summary
Current radiolabeled PSMA-targeting agents for prostate cancer treatment, such as Lu-PSMA-617, have limited supply of AC-PSMA-617 and face challenges in delivering sufficient radiation to tumors, leading to low complete response rates and progressive disease in some patients.
Development of novel compounds with a radioactive metal chelator bound to a radioactive metal, such as Lu-PSMA-617, which modulates albumin binding and PSMA binding to enhance tumor uptake and retention, using compounds like Lu-HTK01169 to improve diagnostic or therapeutic efficacy.
The novel compounds achieve higher tumor uptake and sustained retention, delivering 8.3 times the radiation dose to tumors compared to Lu-PSMA-617, with improved therapeutic effects in mice models, potentially reducing the required dose by a quarter while maintaining efficacy.
Smart Images

Figure 0007592120000054 
Figure 0007592120000055 
Figure 0007592120000056
Abstract
Description
[Technical field]
[0001] The present invention relates to radiolabeled compounds for the selective imaging or treatment of cancer, in particular compounds that target prostate specific membrane antigen. [Background technology]
[0002] Prostate-specific membrane antigen (PSMA) is a transmembrane protein that catalyzes the hydrolysis of N-acetyl-aspartylglutamate to glutamate and N-acetylaspartate. 1 PSMA is not expressed in most normal tissues, but is overexpressed (up to 1,000-fold) in prostate tumors and metastases. PSMA is not expressed in most normal tissues, but is overexpressed (up to 1,000-fold) in prostate tumors and metastases. 2-3 Due to its pathological expression pattern, various radiolabeled PSMA-targeting imaging agents have been designed and evaluated for radiotherapy of prostate cancer. 4-7
[0003] Common radiolabeled PSMA-targeting internal radiotherapy agents are derivatives of lysine-urea-glutamic acid (Lys-urea-Glu), 131 I-MIP-1095, 117 Lu-PSMA I&T is one example. 5-7 Among them, 177 Lu-PSMA-617 is the most investigated agent and is currently in multicenter trials. 7-14 The preliminary data is 177 They showed that Lu-PSMA-617 was effective in treating metastatic prostate cancer, with 32-60% of patients experiencing a 50% or greater reduction in PSA levels and no serious side effects. 7-13 In a phase II Australian trial, objective responses were observed in 82% of patients with measurable nodal or visceral disease. 14 However, complete response rates are low (<7%), with up to 33% of patients 177 The patient still had progressive disease after treatment with Lu-PSMA-617. 7、9-13 Interestingly, a recent report found that177 In patients with advanced metastatic prostate cancer, including one subject whose disease progressed despite Lu-PSMA-617 therapy, 225 Ac-PSMA-617( 177 Lu as α emitter 225 Ac) gave an excellent response. 15
[0004] In internal radiation therapy 225 Despite the great potential of Ac-PSMA-617, 225 The supply of Ac is limited worldwide. 177 Lu is commercially available in large quantities from multiple suppliers, making it more effective 177 Lu-labeled PSMA targeting agents are 225 It may have greater immediate efficacy in internal radiation therapy of prostate cancer than Ac-PSMA-617. 225 Ac-PSMA-617 is highly effective because 177 This may be due to the high linear energy transition of α particles, which results in double-strand breaks that are less susceptible to radiation resistance compared to the indirect damage caused by β particles emitted from Lu. One way to enhance the efficacy of radiation therapy is to 177 The goal of Lu-labeled drugs is to increase the amount of radiation deposited in the tumor per unit of administered radioactivity. 177 Lu could also reduce the cost of therapeutic radiopharmaceuticals by reducing the cost of radioisotopes.
[0005] No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention. Summary of the Invention [Problem to be solved by the invention]
[0006] Disclosed herein are novel compounds that target PSMA. [Means for solving the problem]
[0007] The disclosure provides a compound of formula Ia or formula Ib, or a salt or solvate of a compound of formula Ia or formula Ib: [ka] [In the formula, R 1 teeth [ka] or -(CH2)5CH3; R 2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3; R 3 teeth [ka] and; L is -CH2NH-, -(CH2)2NH-, -(CH2)3NH-, or -(CH2)4NH-; R 4 is a radiometal chelator, optionally having a radiometal X bound thereto; [n is 1 to 3].
[0008] Also disclosed are compounds having formula II, or a salt or solvate of a compound of formula II: [ka] [In the formula, R 2 is I, Br, or methyl; n is 1 to 3; X is absent, 225 Ac or 177 Lu].
[0009] In certain embodiments, when X is a diagnostic radiometal (such as, but not limited to, 64 Cu, 111 In, 89 Zr, 44 Sc, 68Ga, 99m Tc, 86 Y, 152 Tb or 155 Tb) Such compounds can be used to image PSMA-expressing cancer in a subject.Therefore, a method for imaging PSMA-expressing cancer in a subject is also disclosed, which comprises administering to the subject a composition comprising the compound and a pharma-ceutically acceptable excipient; and imaging the tissue of the subject.
[0010] In certain embodiments, X is a therapeutic radiometal, including but not limited to 64 Cu, 67 Cu, 90 Y, 111 In, 114m In, 117m Sn, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 225 Ac, 213 Bi, 224 Ra, 212 Bi, 212 Pb, 225 Ac, 227 Th, 223 Ra, 47 Sc, 186 Re or 188 When the compound is a toxic radioactive metal such as Re), such a compound can be used to treat a PSMA-expressing cancer in a subject. Accordingly, a method of treating a prostate-specific membrane antigen (PSMA)-expressing cancer in a subject is also disclosed, which comprises administering to the subject a composition comprising the compound and a pharma- ceutically acceptable excipient.
[0011] This summary of the invention does not necessarily describe all features of the invention. [Brief description of the drawings]
[0012] These and other features of the present invention will become more apparent from the following description taken in conjunction with the accompanying drawings. [Figure 1]FIG. 1 shows representative displacement curves of 18F-DCFPyL binding to LNCaP prostate cancer cells by Lupa-PSMA-617 and Lu-HTK01169. [Diagram 2] Figure 2 shows SPECT / CT images of (A) 177Lu-labeled PSMA-617 and (B) HTK01169 in mice bearing LNCaP tumor xenografts. Higher and more sustained uptake of 177Lu-HTK01169 in the tumor xenografts was observed. [Figure 3A] Figure 3A is a graph showing the biodistribution of 177Lu-PSMA-617 to selected organs of mice bearing LNCaP tumor xenografts (n>5). Bars from left to right: 1 hour, 4 hours, 24 hours, 72 hours, 120 hours. [Figure 3B] Figure 3B is a graph showing the biodistribution of 177Lu-HTK01169 to selected organs of mice bearing LNCaP tumor xenografts (n>5). Bars from left to right: 1 hour, 4 hours, 24 hours, 72 hours, 120 hours. [Figure 4] Figure 4 is a graph showing the radiation dose (mGy / MBq) delivered by 177Lu-HTK01169 (left bar) and 177Lu-PSMA-617 (right bar) to major organs / tissues in 25-g mice (calculated using OLINDA software). [Diagram 5] Figure 5 shows the radiation dose (mGy / MBq) of 177Lu-PSMA-617 (bottom) and 177Lu-HTK01169 (top) to LNCaP tumors calculated using OLINDA software. These data were obtained for different tumor masses and assume the same tumor uptake (%ID, percent injected dose) and residence time for 177Lu-PSMA-617 and 177Lu-HTK01169. [Figure 6]Figure 6 is a line graph showing overall survival of LNCaP tumor-bearing mice (n=8 per group) injected with saline (control group), 177Lu-PSMA-617 (18.5MBq) or 177Lu-HTK01169 (2.3-18.5MBq). Median survival from shortest to longest: control, 2.3MBq177Lu-HTK01169, 18.5MBq177Lu-PSMA-617, 4.6MBq177Lu-HTK01169, 9.3MBq177Lu-HTK01169, 18.5MBq177Lu-HTK01169. [Figure 7] FIG. 7 shows line graphs of (A) tumor volume and (B) body weight changes over time following treatment of mice with saline. [Figure 8] FIG. 8 shows line graphs of (A) tumor volume and (B) body weight over time after treatment of mice with 177Lu-PSMA-617 (18.5 MBq). [Figure 9] FIG. 9 shows line graphs of (A) tumor volume and (B) body weight changes over time after treatment of mice with 177Lu-HTK01169 (18.5 MBq). [Figure 10] FIG. 10 shows line graphs of (A) tumor volume and (B) body weight changes over time after treatment of mice with 177Lu-HTK01169 (9.3 MBq). [Figure 11] FIG. 11 shows line graphs of (A) tumor volume and (B) body weight changes over time after treatment of mice with 177Lu-HTK01169 (4.6 MBq). [Figure 12] FIG. 12 shows line graphs of (A) tumor volume and (B) body weight changes over time after treatment of mice with 177Lu-HTK01169 (2.3 MBq). [Figure 13]Figure 13 shows maximum intensity projection PET / CT images of 68Ga-HTK03026, 68Ga-HTK03027, 68Ga-HTK03029, and 68Ga-HTK03041 acquired 1 or 3 hours after injection in mice bearing LNCaP tumor xenografts. All 68Ga-labeled compounds are primarily excreted via the renal route. While the tumor uptake of 68Ga-HTK03026, 68Ga-HTK03027, and 68Ga-HTK03029 is comparable, the highest tumor uptake of 68Ga-HTK03041 increases from 1 to 3 hours after injection. [Figure 14] Figure 14 shows maximum intensity projection PET / CT images of 68Ga-HTK03055, 68Ga-HTK03056, and 68Ga-HTK03058 acquired 1 and 3 hours post-injection in mice bearing LNCaP tumor xenografts. All three compounds show some degree of blood pooling, as the heart is clearly visualized in the 1 hour post-injection image. While uptake into the blood (heart) decreases over time (from 1 hour to 3 hours post-injection), uptake into the tumor increases over time. [Figure 15] Figure 15 shows maximum intensity projection PET / CT images of 68Ga-HTK03082, 68Ga-HTK03085, and 68Ga-HTK03086 acquired 1 and 3 hours post-injection in mice bearing LNCaP tumor xenografts. All three compounds are primarily excreted via the renal route. 68Ga-HTK03085 and 68Ga-HTK03086 show significantly higher blood retention compared to 68Ga-HTK03082. Tumor uptake of 68Ga-HTK03085 and 68Ga-HTK03086 also increases over time from 1 to 3 hours post-injection. [Figure 16]Figure 16 shows maximum intensity projection PET / CT images of 68Ga-HTK03087, 68Ga-HTK03089, and 68Ga-HTK03090 acquired at 1 and 3 hours post-injection in mice bearing LNCaP tumor xenografts. 68Ga-HTK03089 and 68Ga-HTK03090 show significantly higher blood retention compared to 68Ga-HTK03087. Tumor uptake of 68Ga-HTK03089 and 68Ga-HTK03090 also increases over time from 1 to 3 hours post-injection. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] As used herein, the terms "comprising," "having," "including," and "comprising," as well as grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and / or method steps. The term "consisting essentially of," when used herein in connection with a composition, use, or method, indicates that additional elements and / or method steps may be present, but that these additions do not substantially affect the function of the recited composition, method, or use. The term "consisting of," when used herein in connection with a composition, use, or method, excludes the presence of additional elements and / or method steps. A composition, use, or method described herein as including certain elements and / or steps may also consist essentially of those elements and / or steps in certain embodiments, and consist of those elements and / or steps in other embodiments, regardless of whether these embodiments are specifically referred to. A use or method described herein as including certain elements and / or steps may consist essentially of those elements and / or steps in certain embodiments, and consist of those elements and / or steps in other embodiments, regardless of whether these embodiments are specifically referred to.
[0014] Reference to an element with the indefinite article "a" does not exclude the presence of a plurality of elements, unless the context clearly requires that only one element is present. The singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. The use of the terms "a" or "an" when used in conjunction with the term "comprising" herein may mean "one," but is not inconsistent with the meaning of "one or more," "at least one," and "one or more than one."
[0015] Unless otherwise stated, the terms "specific embodiment," "various embodiments," "an embodiment," and similar terms include a particular feature for that embodiment alone or in combination with other embodiments described herein, regardless of whether other embodiments are referenced directly or indirectly, and whether the feature or embodiment is described in the context of a method, product, use, composition, compound, etc.
[0016] As used herein, the terms "treat," "treatment," "therapeutic," and the like include amelioration of symptoms, reducing disease progression, improving prognosis, and reducing recurrence of cancer.
[0017] As used herein, the term "diagnostic agent" includes "imaging agents." Thus, "diagnostic radiometals" include radiometals suitable for use as imaging agents.
[0018] The term "subject" refers to an animal (e.g., a mammal or a non-mammal). A subject may be a human or a non-human primate. A subject may be a laboratory mammal (e.g., a mouse, a rat, a rabbit, a hamster, etc.). A subject may be an agricultural animal (e.g., a horse, a sheep, a cow, a pig, a camel, etc.) or a pet (e.g., a dog, a cat, etc.).
[0019] As used herein, the terms "salt" and "solvate" have their usual meaning in chemistry. Thus, when a compound is a salt or solvate, it is associated with an appropriate counterion. Methods of preparing salts or exchanging counterions are well known in the art. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of an appropriate base (e.g., but not limited to, hydroxides, carbonates, bicarbonates, etc. of Na, Ca, Mg, or K), or with the free base forms of these compounds with a stoichiometric amount of an appropriate acid. Such reactions are generally carried out in water or in an organic solvent, or in a mixture of both. The counterion can be changed, for example, by ion exchange techniques such as ion exchange chromatography. All zwitterions, salts, solvates, and counterions are intended unless a particular form is specifically indicated.
[0020] In certain embodiments, the salt or counterion may be pharma- ceutically acceptable for administration to a subject.More generally, for any pharmaceutical composition disclosed herein, non-limiting examples of suitable additives include any suitable buffer, stabilizer, salt, antioxidant, complexing agent, isotonicity agent, cryoprotectant, cryoprotectant, suspending agent, emulsifying agent, antimicrobial agent, preservative, chelating agent, binder, surfactant, wetting agent, non-aqueous vehicle such as fixed oil, or polymer for slow or controlled release.See, for example, Berge et al. 1977. (J. Pharm Sci. 66:1-19), or Remington- The Science and Practice of Pharmacy, 21st edition (Gennaro et al editors. Lippincott Williams & Wilkins Philadelphia), each of which is incorporated by reference in its entirety.
[0021] In one aspect of the invention, there is disclosed a compound of formula Ia or formula Ib, or a salt or solvate of a compound of formula Ia or formula Ib. [ka] [In the formula, R 1 teeth [ka] or -(CH2)5CH3; R 2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3; R 3 teeth [ka] and; L is -CH2NH-, -(CH2)2NH-, -(CH2)3NH-, or -(CH2)4NH-; R 4 is a radiometal chelator, optionally having a radiometal X bound thereto; [n is 1 to 3].
[0022] The wavy line symbol shown through a bond in a chemical formula (e.g., formula Ia or formula Ib) TIFF0007592120000008.tif1125 allows the modification of the R group on one side of the wavy line (e.g., R 1 , R 2 , R 3 ). When R groups are attached at more than one side (e.g., R 3 ), the atoms outside the wavy lines are included to clarify the orientation of the R group; therefore, only the atoms between the two wavy lines constitute the definition of the R group.
[0023] In certain embodiments, the compound is a compound of formula Ia, or a salt or solvate of formula Ia.
[0024] In certain embodiments, the compound is a compound of formula Ib, or a salt or solvate of a compound of formula Ib.
[0025] In one embodiment, R 1teeth [ka] It is.
[0026] In one embodiment, R 1 teeth [ka] It is.
[0027] In one embodiment, R 1 teeth [ka] It is.
[0028] In one embodiment, R 1 teeth [ka] It is.
[0029] In one embodiment, R 1 is -(CH2)5CH3.
[0030] R 1 forms a side chain of an amino acid residue (e.g., 2-naphthylalanine, etc.). In certain embodiments, the amino acid is an L-amino acid, i.e., [ka] (e.g., L-2-naphthylalanine, etc.). In certain embodiments, the amino acid is a D-amino acid. [ka] (For example, D-2-naphthylalanine, etc.).
[0031] In one embodiment, R 1 teeth [ka] It is.
[0032] In one embodiment, R 1 teeth [ka] It is.
[0033] In one embodiment, R 1 teeth [ka] It is.
[0034] In one embodiment, R 1 teeth [ka] It is.
[0035] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
[0036] As shown in formulas Ia and Ib, the benzene ring contains one R 2 If it is not hydrogen, it is R 2 can be in the para, meta, or ortho position of the benzene ring, i.e. [ka]
[0037] In one embodiment, R 2 In one embodiment, R 2 is in the meta position. 2 is in the ortho position.
[0038] In one embodiment, R 2 is H. In one embodiment, R 2 is I. In one embodiment, R 2 is Br. In one embodiment, R 2is F. In one embodiment, R 2 is Cl. In one embodiment, R 2 is OH. In one embodiment, R 2 is OCH. In one embodiment, R 2 is NH. In one embodiment, R 2 is NO2. In one embodiment, R 2 is CH3.
[0039] In one embodiment, R 3 teeth [ka] (i.e., a Gly residue).
[0040] In one embodiment, R 3 teeth [ka] (i.e., an Asp residue). In some embodiments, the Asp residue is D-Asp. In some embodiments, the Asp residue is L-Asp.
[0041] In one embodiment, R 3 teeth [ka] (i.e., a Glu residue). In some embodiments, the Glu residue is D-Glu. In some embodiments, the Glu residue is L-Glu.
[0042] In one embodiment, R 3 teeth, [ka] It is.
[0043] In one embodiment, R 3 teeth, [ka] It is.
[0044] In one embodiment, R 3 teeth, [ka] It is.
[0045] R 4 X may be any radiometal chelator suitable for binding to the radiometal of interest (i.e., X) and functionalized for binding to an amino group. Many suitable radiometal chelators are known. See, for example, Orvig, Chem. Soc. Rev., 2014, 43, 260-290, which is incorporated by reference in its entirety. In certain embodiments, R 4 teeth: DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or its derivatives, such as, but not limited to, DOTAGA; TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) or its derivatives, such as, but not limited to, CB-TE2A (4,11-bis-(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane); SarAr(1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexazabicyclo[6.6.6]-eicosane-1,8-diamine or a derivative thereof; NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) or its derivatives, such as, but not limited to, NODAGA; TRAP (1,4,7-triazacyclononane-1,4,7-tris[methyl(2-carboxyethyl)phosphinic acid) or its derivatives; HBED (N,N0-bis(2-hydroxybenzyl)-ethylenediamine-N,N0-diacetic acid) or its derivatives; 2,3-HOPO (3-hydroxypyridin-2-one) or its derivatives; PCTA (3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),11,13-triene-3,6,9,-triacetic acid) or its derivatives; DFO (desferrioxamine) or its derivatives, such as tetrahydroxamate DFO * (DFO-star), but not limited to; DTPA (diethylenetriaminepentaacetic acid) or its derivatives, such as, but not limited to, CHX-DTPA (2-(p-isothiocyanatobenzyl)-cyclohexyldiethylenetriaminepentaacetic acid); OCTAPA (N,N0-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N0-diacetic acid) or a derivative thereof (e.g., a picolinic acid derivative); or H2-MACROPA (N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6) or its derivatives It is.
[0046] In certain embodiments, X is absent.
[0047] In certain embodiments, X is a therapeutic radiometal. For example, X is 64 Cu, 67 Cu, 90 Y, 111 In, 114m In, 117m Sn, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 225 Ac, 213 Bi, 224 Ra, 212 Bi, 212 Pb, 225 Ac, 227 Th, 223 Ra, 47 Sc, 186 Re, or 188 In one embodiment, X can be, but is not limited to, Re. 64 In one embodiment, X is Cu. 67In one embodiment, X is Cu. 90 In one embodiment, X is 111 In one embodiment, X is In. 114m In one embodiment, X is In. 117m In one embodiment, X is Sn. 153 In one embodiment, X is Sm. 149 In one embodiment, X is 161 In one embodiment, X is 177 In one embodiment, X is 225 In one embodiment, X is 213 In one embodiment, X is Bi. 224 In one embodiment, X is 212 In one embodiment, X is Bi. 212 In one embodiment, X is 225 In one embodiment, X is 227Th In one embodiment, X is 223 In one embodiment, X is 47 In one embodiment, X is 186 In one embodiment, X is Re. 188 Re.
[0048] In certain embodiments, X is a diagnostic radiometal. For example, X is 64 Cu, 111 In, 89 Zr, 44 Sc, 68 Ga, 99m Tc, 86 Y, 152 Tb or 155 In one embodiment, X can be, but is not limited to, Tb. 64 In one embodiment, X is Cu. 111 In one embodiment, X is In. 89 In one embodiment, X is Zr. 44 In one embodiment, X is 68 In one embodiment, X is 99m In one embodiment, X is86 In one embodiment, X is 152 In one embodiment, X is 155 Tb.
[0049] In one embodiment, R 1 teeth [ka] and R 3 teeth [ka] [In the formula, R 2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3, X is absent, 90 Y, 67 Ga, 68 Ga, 177 Lu, 225 Ac, or 111 In]. Some of these embodiments include R 2 is in the para position. Certain of these embodiments include 2 is I. In some of these embodiments, X is 177 Lu, and in other embodiments, X is 225 It is Ac.
[0050] In one embodiment, R 1 teeth [ka] and R 3 teeth [ka] [In the formula, R 2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3, X is absent, 90 Y, 67 Ga, 68 Ga, 177Lu, 225 Ac, or 111 In]. Some of these embodiments include R 2 is in the para position. Certain of these embodiments include 2 is I. In some of these embodiments, X is 177 Lu, and in other embodiments, X is 225 In some of these embodiments, n is 3.
[0051] In certain embodiments, L is -CH2NH-. In certain embodiments, L is -(CH2)2NH-. In certain embodiments, L is -(CH2)3NH-. In certain embodiments, L is -(CH2)4NH-.
[0052] L forms a side chain of an amino acid residue (e.g., 2,3-diaminopropionic acid (Dap), 2,4-diaminobutanoic acid (Dab), ornithine (Orn), or lysine (Lys)). In certain embodiments, the amino acid is an L-amino acid, i.e. [ka] (e.g., L-Dap, L-Dab, L-Orn, L-Lys). In some embodiments, the amino acid is a D-amino acid. [ka] (e.g., D-Dap, D-Dab, D-Orn, or D-Lys).
[0053] In one embodiment, the amino acid residue formed by L is an L-amino acid, and R 1 In one embodiment, the amino acid residue formed by L is a D-amino acid and R 1 In one embodiment, the amino acid residue formed by L is an L-amino acid and R 1In one embodiment, the amino acid residue formed by L is a D-amino acid and R 1 The amino acid residue formed by is an L-amino acid.
[0054] In certain embodiments, the compound is a compound having formula II, or a salt or solvate of a compound of formula II: [ka] [In the formula, R 2 is I, Br, or methyl; n is 1 to 3; X is absent, 225 Ac or 177 Lu]. In some of these embodiments, R 2 is I. In some of these embodiments, R 2 In some of these embodiments, R is Br. 2 is methyl. In some of these embodiments, n is 1. In some of these embodiments, n is 2. In some of these embodiments, n is 3. In some of these embodiments, X is absent. In some of these embodiments, X is 177 Lu and attached to the DOTA group. In some of these embodiments, X is 225 Ac and is attached to the DOTA group.
[0055] In certain embodiments, the compound has formula III, or is a salt or solvate of a compound of formula III: [ka] (III, also called "X-HTK01169", where X is absent, 90 Y, 67 Ga, 68 Ga, 177 Lu, 225 Ac, or 111 In.177 When Lu, the compound has the structure shown below, or a salt or solvate thereof: [ka] (Lu-HTK01169).
[0056] The synthetic schemes for HTK01169 and Lu-HTK01169 are described below in Example 1. Example 2 describes synthetic schemes for preparing metal chelating PSMA binding compounds incorporating multiple options for the R groups of formulas Ia and Ib.
[0057] The above compounds modulate albumin binding and PSMA binding (e.g., compared to Lu-PSMA-617) and modulate (e.g., enhance) tumor uptake / retention to provide alternative or improved diagnostic or therapeutic agents for PSMA-expressing cancers. In particular, the above compounds contain an albumin-binding domain that increases the blood circulation time of the compound, i.e., [ka] (e.g., the iodophenylbutyryl group of Lu-HTK01169; see also PCT Patent Publication No. WO2008 / 053360). 2 and / or changing the value of n (i.e., n=1, 2, or 3), and / or R 3Modification of the albumin binding group by introducing (e.g., addition of Gly or carboxylate-containing Asp or Glu) can modulate (increase or decrease) the albumin binding strength (i.e., binding affinity) of the compound, thereby modulating the resulting blood circulation time of the compound. Without being bound by theory, a compound that binds too strongly to albumin (i.e., has too high a binding affinity to albumin) will result in the compound being retained in the blood circulation for too long, resulting in very low accumulation in the tumor. This will result in low overall tumor uptake and too high a radiation dose to the bone marrow. At the same time, an albumin binding affinity that is too weak will result in the compound being rapidly cleared from the blood circulation, decreasing the opportunity for accumulation in the tumor. Additionally, the above compounds also contain a Lys-urea-Glu PSMA binding moiety. The PSMA binding strength of the compound can be determined by the R 1 can be adjusted (increased or decreased) by modifying. Without wishing to be bound by theory, the adjusted tumor uptake / retention of the above compounds may be due to adjusted albumin binding and / or PSMA binding strength (e.g., compared to Lu-PSMA-617). The diagnostic or therapeutic effect can be further adjusted by varying the radiometal conjugated to the chelator. As shown by the examples below, the above variables have been adjusted in the above compounds to enhance PSMA-expressing tumor uptake / retention and thus diagnostic or therapeutic effect.
[0058] When X is a diagnostic radioactive metal, the use of certain embodiments of the compound is disclosed for preparing radiolabeled tracer for imaging PSMA-expressing tissue of a subject.Also disclosed is a method for imaging PSMA-expressing tissue of a subject, comprising administering to a subject a composition comprising certain embodiments of the compound and a pharma-ceutically acceptable excipient; and imaging the tissue of the subject (e.g., using positron emission tomography (PET)).When the tissue is diseased tissue (e.g., cancer that expresses PSMA), a treatment that targets PSMA can be selected to treat the subject.
[0059] When X is a therapeutic radiometal, the use of certain embodiments of the compound (or pharmaceutical composition thereof) for treating PSMA-expressing disease (e.g., cancer) in a subject is disclosed.Therefore, the use of the compound in the manufacture of a medicament for treating PSMA-expressing disease in a subject is provided.Also provided is a method for treating PSMA-expressing disease in a subject, comprising administering to the subject a composition comprising the compound and a pharmaceutical acceptable excipient.For example, but not limited to, the disease can be PSMA-expressing cancer.
[0060] Expression of PSMA has been detected in various cancers (e.g., Rowe et al., 2015, Annals of Nuclear Medicine 29:877-882; Sathekge et al., 2015, Eur J Nucl Med Mol Imaging 42:1482-1483; Verburg et al., 2015, Eur J Nucl Med Mol Imaging 42:1622-1623; and Pyka et al., J Nucl Med November 19, 2015 jnumed.115.164442). Thus, without limitation, the PSMA-expressing cancer can be prostate cancer, kidney cancer, breast cancer, thyroid cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, lung cancer, liver cancer, brain cancer, melanoma, neuroendocrine tumor, ovarian cancer or sarcoma. In some embodiments, the cancer is prostate cancer. EXAMPLES
[0061] The present invention is further illustrated in the following examples.
[0062] Example 1: 177 Lu-HTK011691. 1. Materials and Methods 1.11 General method All chemicals and solvents were obtained from commercial sources and used without further purification. Human serum for protein binding assays was obtained from Innovative Research (Novi, MI). PSMA-617 and HTK01169 were synthesized using solid-phase methods on an Aapptec (Louisville, KY) Endeavour 90 peptide synthesizer. Mass spectrometry was performed using an AB SCIEX (Framingham, MA) 4000 QTRAP mass spectrometer system equipped with an ESI ion source. Non-radioactive and 177 Purification and quality control of Lu-labeled peptides were performed on an Agilent (Santa Clara, CA) HPLC system equipped with a model 1200 quaternary pump and a model 1200 UV absorbance detector. The radio-HPLC system was equipped with a Bioscan (Washington, DC) NaI scintillation detector. The HPLC columns used were a Phenomenex (Torrance, CA) semi-preparative column (Luna C18, 5μ, 250 × 10 mm) and a Phenomenex analytical column (Luna C18, 5μ, 250 × 4.6 mm). 177 The radioactivity of the Lu-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC®-25R / W dose calibrator.
[0063] 1.12 Solid-phase synthesis of PSMA-617 and HTK01169 The synthesis of PSMA-617 and its albumin-binder-containing derivative HTK01169 was performed according to reported procedures. 16 from Fmoc-Lys(ivDde)-Wang resin. After coupling of the isocyanate of the t-butyl-protected glutamyl moiety, 17 The ivDde protecting group was removed with 2% hydrazine in N,N-dimethylformamide (DMF). Coupling of Fmoc-2-Nal-OH, Fmoc-tranexamic acid, and DOTA-tris(t-bu) ester was followed by cleavage with trifluoroacetic acid (TFA) to give the crude PSMA-617. A semi-preparative column containing 25% acetonitrile in water with 0.1% TFA was used at 4.5 mL / min (tR After HPLC purification at a flow rate of 1000 s, 1000 s, 10.5 min, PSMA-617 was obtained in 25% yield. ESI-MS: calculated [M+H] for PSMA-617 + C 49 H 72 N9O 16 1042.5; Measured value [M+H] + 1042.6.
[0064] For the synthesis of HTK01169, Fmoc-Lys(ivDde)-OH was coupled to the sequence following Fmoc-tranexamic acid. Elongation was continued by adding Fmoc-Glu(tBu)-OH and 4-(p-iodophenyl)butyric acid to the N-terminus. The ivDde protecting group was then removed with 2% hydrazine in DMF and DOTA-tris(t-bu) ester was attached to the Lys side chain. The peptide was cleaved by TFA treatment and purified by HPLC using a semi-preparative column with 0.1% TFA in 37% acetonitrile in water at a flow rate of 4.5 mL / min (t R = 9.7 min). The yield of HTK01169 was 21%. ESI-MS: Calculated value of HTK01169 [M+H] + C 70 H 100 N 12 O 21 I 1571.6; Measured value [M+H] + 1571.7.
[0065] 1.13 Synthesis of Lu-PSMA-617 and Lu-HTK01169 A solution of PSMA-617 (5.5 mg, 5.3 μmol) or HTK01169 (4.1 mg, 2.6 μmol) was incubated with LuCl3 (5 equiv.) in NaOAc buffer (0.1 M, 500 μL, pH 4.2) at 90 °C for 15 min, and then purified by HPLC using a semi-preparative column. For Lu-PSMA-617, the HPLC conditions were 25% acetonitrile in water containing 0.1% TFA, at a flow rate of 4.5 mL / min (t R = 9.7 min). The yield was 62%. ESI-MS: Calculated value [M+H] + (Lu-PSMA-617)C 49H 69 N9O 16 [Lu] 1214.4; Found value [M+H] + 1214.4. For Lu-HTK01169, the HPLC conditions were 37% acetonitrile aqueous solution containing 0.1% TFA, flow rate 4.5 mL / min (t R = 10.0 min). The yield was 31%. ESI-MS: Calculated value [M+H] + (Lu-HTK01169) C 70 H 97 N 12 O 21 I [Lu] 1743.5; Measured value [M+H] + 1743.9.
[0066] 1.14 In vitro competitive binding assays As previously reported, LNCaP prostate cancer cells and radioligand 18 An in vitro competitive binding assay was performed using F-DCFPyL. 18 Briefly, LNCaP cells (400,000 / well) were plated onto 24-well poly-D-lysine coated plates for 48 h. Growth medium was removed and replaced with HEPES buffered saline (50 mM HEPES, pH 7.5, 0.9% sodium chloride), and cells were incubated at 37° C. for 1 h. 18 F-DCFPyL (0.1 nM) was added (in triplicate) to each well containing various concentrations (0.5 mM to 0.05 nM) of test compound (Lu-PSMA-617 or Lu-HTK01169). Non-specific binding was measured in the presence of 10 μM non-radiolabeled DCFPyL. The assay mixture was further incubated for 1 h at 37 °C with gentle agitation. Then, the buffer and hot ligand were removed and the cells were washed twice with cold HEPES-buffered saline. To harvest the cells, 400 μL of 0.25% trypsin solution was added to each well. Radioactivity was measured in a PerkinElmer (Waltham, MA) Wizard2 2480 automated gamma counter. Non-linear regression analysis and K i Calculations were performed using GraphPad Prism 7 software.
[0067] 1.15 177 Lu-PSMA-617 and 177 Synthesis of Lu-HTK01169 177 LuCl3 (329.3–769.9 MBq in 10–20 μL) was added to a solution of PSMA-617 or HTK01169 (25 μg) in NaOAc buffer (0.5 mL, 0.1 M, pH 4.5). The mixture was incubated at 90 °C for 15 min and then purified by HPLC. 177 Lu-PSMA-617 and 177 The HPLC purification conditions for Lu-HTK01169 (semi-prep column, 4.5 mL / min) were 23% and 36% acetonitrile in water (0.1% TFA), respectively. 177 Lu-PSMA-617 and 177 The retention times of Lu-HTK01169 were 15.0 and 13.8 min, respectively. Quality control was performed on an analytical column using the corresponding purification solvent conditions at a flow rate of 2 mL / min. 177 Lu-PSMA-617 and 177 The retention time of Lu-HTK01169 was approximately 5.5 minutes in both cases.
[0068] 1.16 Plasma Protein Binding Assays Plasma protein binding assays were performed according to literature methods. 19 In simple terms, 37kBq 177 Lu-PSMA-617 or 177 Lu-HTK01169 was added to 200 μL human serum in 50 μL PBS, and the mixture was incubated at room temperature for 1 min. The mixture was then loaded onto a membrane filter (Nanosep®, 30 K, Pall Corporation, USA) and centrifuged for 45 min (30, 130×g). Saline (50 μL) was added and centrifugation continued for another 15 min. The top part with the membrane filter and the bottom part with the solution were counted in a gamma counter. As a control, saline was used instead of human serum.
[0069] 1.17 SPECT / CT Imaging, Biodistribution and Internal Radiotherapy Studies SPECT / CT imaging and biodistribution of NOD-scid IL2Rgamma null (NSG) male mice were used, and internal radiotherapy studies were performed using NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl Experiments were performed using 1 × 10 1 / SzJ(NRG) male mice. Mice were housed and experiments were performed in accordance with guidelines established by the Canadian Council on Animal Care and approved by the Animal Ethics Committee of the University of British Columbia. Mice were anesthetized with inhalational 2% isoflurane in oxygen and injected with 1 × 10 7 LNCaP cells were implanted subcutaneously. Mice were used for the study when tumors reached a diameter of 5–8 mm 5–6 weeks after inoculation.
[0070] SPECT / CT imaging experiments were performed using a MILabs (Utrecht, The Netherlands) U-SPECT-II / CT scanner. Each tumor-bearing mouse was anesthetized (2% isoflurane in oxygen) and injected with ~37 MBq of CT-T cells via the tail vein. 177Lu-labeled PSMA-617 or HTK01169 was injected. Mice were allowed to recover, roam freely in their cages, and imaged 4, 24, 72, and 120 hours after injection. At each time point, mice were sedated again and placed in the scanner. First, a 5-minute CT scan was performed at a voltage setting of 60 kV and a current of 615 μA for anatomical reference, followed by a 60-minute static emission scan acquired in list mode with an ultra-high-resolution multi-pinhole rat mouse (1 mm pinhole size) collimator. Data were reconstructed using U-SPECT II software in three energy windows with a window width of 20%. The photopeak window was centered at 208 keV, and the lower and upper scatter windows were centered at 170 keV and 255 keV, respectively. Images were reconstructed using an ordered subset expectation-maximization algorithm (3 iterations, 16 subsets), and a 0.5 mm post-processing Gaussian filter. Images were attenuation corrected to the time of injection in PMOD (PMOD Technologies, Switzerland) and converted to DICOM for qualitative visualization in Inveon Research Workplace software (Siemens Medical Solutions USA, Inc.).
[0071] For biodistribution studies, mice were treated as described above. 177 Lu-labeled PSMA-617 or HTK01169 (2–4 MBq) were injected into the mice. At the designated time points (1, 4, 24, 72, or 120 h post-injection), the mice were euthanized by CO2 inhalation. Blood was immediately collected from the heart, and the organs / tissues of interest were harvested. The collected organs / tissues were weighed and counted using an automated gamma counter. For blocking studies, the mice were 177 Lu-HTK01169 (2–4 MBq) and 50 nmol of non-radioactive standard were co-injected, and organs / tissues of interest were harvested 4 h post-injection.
[0072] In the radiotherapy study, mice with tumors were given saline (control group); 177 Lu-PSMA-617 (18.5MBq) or177 Lu-HTK01169 (18.5, 9.3, 4.6, or 2.3 MBq) (n=8 per group). Tumor size and body weight were measured twice weekly from the day of injection (day 0) until completion of the study (day 120). Endpoint criteria were >20% body weight loss, tumor volume >1000 mm 3 or active ulceration of the tumor.
[0073] 1.18 Radiation Dosimetry Calculations Internal dosimetry estimates were calculated using Organ-Level Internal Dose Assessment (OLINDA) software v.2.0.3 7 These estimates are based on the 25 g MOBY phantom for mice. 38 For humans, a NURBS model of an adult male is used. 39 The tumors were modeled using a previously reported unit density sphere model. 40 All phantom and sphere models can be used in OLINDA and require the input of the total number of decays normalized by the injected activity per organ / tumor of origin (units MBq × h / MBq).
[0074] Biodistribution data (available in Tables 1 and 2 below) were used to determine the kinetic input values required for OLINDA. First, each value was allowed to decay to the corresponding time point (table values are given at the time of injection). Next, the uptake data (%ID / g) for each organ at various time points were fitted to a single exponential function using in-house software developed in Python.
number
number
[0075] In the case of the mouse, the adrenal glands, blood, fat, muscle, and seminal vesicles were not modeled in the phantom: these organs were grouped together and included in what OLINDA calls the rest of the body.
[0076] Extrapolation of mouse biodistribution data to humans was performed according to Kirschner et al. 41 This was done using the method proposed by and the following equation:
number
[0077] where m organ where σ is the organ mass and M represents the total body mass. The subscript indicates whether the value corresponds to a human or mouse. Organ masses and total body weight were taken from the simulated mass of the OLINDA phantom. Since the biodistribution data do not distinguish between the left colon, right colon, and rectum present in the OLINDA human phantom, these three regions of the intestine were assumed to have the same radioactivity uptake (%ID / g) as the large intestine in the biodistribution. The %ID / g of blood was assumed relative to the cardiac contents of the phantom. This value was calculated using the method described by Wessels et al. 42 The data was also used to calculate bone marrow uptake based on the phantom weight, assuming a hematocrit ratio of 0.40, based on the patient values presented in this study. Finally, the red bone marrow value used blood measurements scaled by a factor of 0.32. For humans, fat, muscle, and seminal vesicles present in the biodistribution data were not modeled in the phantom, so the number of decays present in these regions were included in the rest of the body. The data was fitted again as for mice, and the value for the total number of decays was entered into OLINDA (units MBq × h / MBq).
[0078] Finally, the number of disruptions in the tumor was also calculated based on the mouse biodistribution data and the values were input into the sphere model available in OLINDA.
[0079] 1.2 Results 1.21 Peptide synthesis and radiochemistry PSMA-617 and HTK01169 were synthesized in 25% and 21% yields, respectively. After reaction with LuCl3 and purification by HPLC, Lu-PSMA-617 and Lu-HTK01169 were obtained in 62% and 31% yields, respectively. The identities of PSMA-617, HTK01169, and their Lu complexes were confirmed by MS analysis.
[0080] 177 Lu labeling was carried out in acetate buffer (pH 4.5) at 90°C, followed by purification by HPLC. 177 Lu-PSMA-617 was obtained with a molar activity of 782 ± 43.3 GBq / μmol in a radiochemical yield of 86.0 ± 1.7% (n = 3) and a radiochemical purity of >99%. 177 Lu-HTK01169 was obtained in a radiochemical yield of 63.0 ± 16.2% (n = 4) with a molar activity of 170 ± 73.6 GBq / μmol and a radiochemical purity of >99%.
[0081] 1.22 Binding to PSMA and serum proteins Lu-PSMA-617 and Lu-HTK01169 dose-dependently inhibited the binding of PSMA to LNCaP cells. 18 F-DCFPyL binding (Figure 1) and their calculated K i The values were 0.24 ± 0.06 and 0.04 ± 0.01 nM, respectively (n = 3). After incubation with saline and centrifugation, the radioactivity bound to the filters was 177 Lu-PSMA-617 and 177 The radioactivity bound to the filters was 5.21 ± 1.42 and 25.8 ± 3.42% for Lu-HTK01169, respectively (n = 3). When saline was replaced with human serum, the radioactivity bound to the filters was 177 Lu-PSMA-617 and 177 For Lu-HTK01169, under the same conditions, it increased to 82.7 ± 0.32 and 99.2 ± 0.02%, respectively (n = 3).
[0082] 1.23 SPECT / CT Imaging and Biodistribution SPECT / CT contrast examination 177 Lu-PSMA-617 and 177 Both Lu-HTK01169 and HTK01169 were primarily excreted via the renal route, especially at early time points (4 and 24 h; Figure 2 ). 177 The results showed that Lu-HTK01169 has high renal retention. Higher and sustained tumor uptake was observed. 177 This was observed in Lu-HTK01169. 177 Lu-PSMA-617 and 177 The biodistribution data of Lu-HTK01169 are shown in Figures 3A and 3B (see also Tables 1 and 2). These data were consistent with the observations from SPECT / CT images. [Table 1] [Table 2]
[0083] 177 Lu-PSMA-617 was rapidly cleared from blood and non-target organs / tissues. One hour after injection, only 0.68 ± 0.23%ID / g remained in the blood. Uptake was observed in PSMA-expressing tissues, including spleen (3.34 ± 1.77%ID / g), adrenal glands (4.88 ± 2.41%ID / g), kidneys (97.2 ± 19.4%ID / g), lungs (1.34 ± 0.39%ID / g), and LNCaP tumors (15.1 ± 5.58%ID / g). 20-21 Tumor uptake gradually decreased to 7.91 ± 2.82% ID / g at 120 hours post-injection. Rapid clearance from other tissues / organs may account for the difference between tumor and background uptake. 177 The contrast ratio of Lu-PSMA-617 improved over time (Table 1 above).
[0084] When using built-in albumin binder, 177 The blood clearance of Lu-HTK01169 is 177Lu-PSMA-617 (Figures 3A and 3B). 177 Tumor uptake of Lu-HTK01169 increased continuously at early time points, peaked at 24 h post-injection (55.9 ± 12.5% ID / g) and persisted over the course of the study (56.4 ± 13.2% ID / g at 120 h). 177 Similar to Lu-PSMA-617, uptake was also observed in the spleen, adrenal glands, kidneys, and lungs (Table 2 above). The sustained uptake in the tumor and relatively rapid clearance from other organs / tissues may explain the differences in tumor and background tumor uptake. 177 Lu-PSMA-617 contrast ratio improved over time. Compared to biodistribution data collected at the same time point (4 h), blocking with the cold standard reduced uptake in all collected tissues / organs, especially in PSMA-expressing kidneys (125 ± 16.4 vs. 5.50 ± 1.95%ID / g) and LNCaP tumors (55.9 ± 12.5 vs. 1.70 ± 0.28%ID / g).
[0085] 1.24 Radiation Dosimetry Calculations Based on the biodistribution data obtained from tumor-bearing mice, estimates of the radiation dose delivered to the major organs / tissues of the mice were calculated using OLINDA software. The results are shown in Figure 4 and Table 3. Here, both the input kinetics of the original organ (MBq-h / MBq) and the dose to the target organ (mGy / MBq) calculated from the data fit are shown. 177 Compared with Lu-PSMA-617, 177 Lu-HTK01169 is 177 All major organs were delivered 9.4-23.1-fold higher radiation doses, except for the bladder, which received a 1.5-fold higher radiation dose from Lu-PSMA-617. [Table 3]
[0086] Similar results were obtained for the calculated radiation doses delivered to human organs / tissues (Table 4). Most human organs / tissues were 177The brain, heart, red bone marrow, and spleen received 11.9–24.9 times higher radiation doses from Lu-HTK01169. 177 Lu-HTK01169 received 6-fold, 50.4-fold, 30.4-fold, and 28.1-fold higher doses. The bladder 177 received a 1.3-fold higher radiation dose from Lu-PSMA-617. [Table 4]
[0087] 177 Lu-PSMA-617 and 177 The behavior of radiation dose delivered to a unit density sphere based on kinetics in LNCaP tumors from Lu-HTK01169 is shown in Figure 5 and Table 5. The kinetic uptake values used as input in OLINDA are: 177 Lu-PSMA-617 and 177 For Lu-HTK01169, the values were 3.80 MBq-h / MBq and 31.72 MBq-h / MBq, respectively. 177 Lu-HTK01169 inhibits LNCaP tumors regardless of the size of the simulated spheres (tumors). 177 It delivered an 8.3-fold higher radiation dose than Lu-PSMA-617. [Table 5]
[0088] 1.25 Internal Radiation Therapy Testing The results of the internal radiation therapy study are shown in Table 6 and Figure 6, and the time course of LNCaP tumor volume and mouse body weight after treatment are shown in Figures 7 to 12. The tumor volume of the control group (group A in Table 6, Figure 7(A)) increased continuously after treatment (saline injection), and the median survival time of the control group was only 14 days (when the tumor volume was 1000 mm 3 Mice were euthanized when they reached 177Tumors in mice treated with Lu-PSMA-617 (18.5 MBq, group B in Table 6, Fig. 8A) initially shrank but later regrew, and median survival improved to 58 days. 177 The change in tumor size over time in mice treated with Lu-HTK01169 (Table 6, groups C–F, Figures 9(A)–12(A)) depended on the injected radioactivity, with higher radioactivity leading to more effective and sustained tumor growth inhibition. 177 The median survival times for the groups of mice treated with Lu-HTK01169 were >120, 103, 61, and 28 days, respectively. No weight loss was observed in all mice, regardless of treatment (Figures 7(B)-12(B)), and 18.5 MBq 177 All mice treated with Lu-HTK01169 (group C in Table 6) survived to the end of the study (day 120). [Table 6]
[0089] 1.3 Discussion The use of small molecule albumin binders to extend drug circulation time and maximize tumor uptake has become an attractive strategy for the design of internal radiotherapeutic agents. Pioneering work was mainly carried out by scientists at ETH Zurich using 4-(p-iodophenyl)butyric acid as albumin-binding motif and D-Lys acylated at the ε-amino group. 22 Previous work has focused on applying this strategy to the design of radiopharmaceuticals targeted to the folate receptor. 23 Folate receptor α and proton-coupled folate transporters are highly expressed in renal proximal tubules, so radiolabeled folate derivatives generally result in very high and sustained renal uptake. 23 Radiolabeled folic acid derivatives with built-in albumin binders have been reported to significantly prolong blood residence time, increase tumor uptake, and improve tumor-to-kidney uptake ratios. 23
[0090] Recently, we have also attempted to use this strategy to design PSMA-targeted radiotherapeutic drugs that carry an albumin-binding motif. 24-28 Among the reported albumin-binding PSMA-targeting therapeutics, 177 Lu-PSMA-ALB-02, 177 Lu-PSMA-ALB-056 and 177 Lu-RPS-063 targets PSMA-expressing tumors 177 It was shown to deliver approximately 1.8, 2.3, and 3.8 times higher radiation doses than Lu-PSMA-617. 26-28 Furthermore, in an internal radiotherapy study in mice bearing PSMA-expressing PC-3 PIP tumors, 177 Lu-PSMA-ALB-056 was further evaluated. 27 177 Lu-PSMA-617 or 177 Mice treated with Lu-PSMA-ALB-056 had an increased median survival time compared to saline-treated control mice. Most importantly, 2MBq 177 When Lu-PSMA-ALB-056 was used, 5MBq 177 It was able to result in slightly better median survival compared with the use of Lu-PSMA-617 (36 vs 32 days).
[0091] In this example, the most studied PSMA-targeted radiotherapy agent 177 To further improve the tumor uptake of Lu-PSMA-617, conjugation of a novel albumin binder was used. The most common albumin-binding motif reported in the literature consisted of D-Lys acylated at the ε-amino group with 4-(p-iodophenyl)butyric acid. 22-23 The α-carboxyl group of D-Lys is part of the albumin binding motif and is therefore unavailable for conjugation to peptides by solid phase synthesis. 29As shown in the structural formula of Lu-HTK01169, a Glu residue is used instead of D-Lys. As a result, the carboxyl group of the Glu side chain was available for conjugation to albumin, and the α-carboxyl group was used for conjugation to peptides by solid-phase synthesis. As shown in this example, modification of the linker between the DOTA chelator and the PSMA target Lys-urea-Glu did not adversely affect the therapeutic effect, confirming reports that such linker modifications are well tolerated. 17 Indeed, as shown in this example, Lu-HTK01169 was observed to have a 6-fold increase in PSMA binding compared to Lu-PSMA-617 (K i Values: 0.04±0.01 vs 0.24±0.06 nM). Without wishing to be bound by theory, the improved PSMA binding may be due to the introduction of the highly lipophilic 4-(p-iodophenyl)butyryl group.
[0092] 177 The ability of Lu-HTK01169 to bind albumin was assessed by a plasma protein binding assay. 177 Under the same conditions, in contrast to Lu-PSMA-617, which was ca. 17% 177 Lu-HTK01169 was less than 1%, demonstrating the ability of the albumin binder modified derivatives to interact with plasma proteins.
[0093] The addition of an albumin binder to extend blood residence time and maximize tumor uptake was confirmed by SPECT / CT and biodistribution studies. 177 Lu-HTK01169 improved peak tumor uptake ( 177 Lu-HTK01169: 55.9 ± 12.5%ID / g; 177 Lu-PSMA-617: 15.1 ± 5.58% ID / g) but most importantly, 177 Uptake was sustained rather than declining over time as with Lu-PSMA-617. Without wishing to be bound by theory, this may be due, in part, to improved PSMA binding of Lu-HTK01169 over Lu-PSMA-617. 177The combination of longer residence time and improved uptake compared to Lu-PSMA-617 resulted in 177 The radiation dose was 8.3 times that of Lu-PSMA-617. 225 Radioisotopes with longer half-lives, such as Ac (t 1 / 2 : 225 Ac, 9.95d; 177 Lu, 6.65 d) may be more important than the currently used 225 Ac is 229 It is extracted from Th and is in limited supply. 30-31 225 From Ac-PSMA-617 225 By switching to Ac-HTK01169, 225 The number of patients that can be treated with Ac-labeled PSMA-targeted radioligands may be significantly increased.
[0094] In this embodiment, about 37 MBq 177 Lu-PSMA-617 or 177 We demonstrated that injection of Lu-HTK01169 rapidly reduced the size of LNCaP tumor xenografts over time (Figure 2). The approximately 37 MBq of injected radioactivity used to acquire high-resolution SPECT images was sufficient to treat LNCaP tumors. 177 Therefore, in this internal radiotherapy trial, 18.5 MBq of 177 Lu-PSMA-617 or 177 Lu-HTK01169, as well as half (9.3MBq), quarter (4.6MBq), or eighth (2.3MBq) doses 177 The median survival times of mice treated with Lu-HTK01169 were compared. As expected from the dosimetry data, 177 The 1 / 8 dose (2.3MBq) of Lu-HTK01169 is 177 When compared with that of Lu-HTK01169 (18.5MBq, Table 6), it did not result in a similar median survival time. However, a quarter of the dose (4.5MBq) 177The median survival time of mice treated with Lu-HTK01169 was 18.5 MBq 177 This was observed to be slightly superior to that in mice treated with Lu-PSMA-617 (61 vs 58 days, Table 6).
[0095] Among the reported albumin-binder-conjugated PSMA-targeted radiotherapeutic agents, 177 Only Lu-PSMA-ALB-056 was evaluated in a radiotherapy trial and was 177 Compared with Lu-PSMA-617. 27 The findings of this embodiment, 177 There are two main differences from the findings reported by Umbricht et al. for Lu-PSMA-ALB-056. 27 As a tumor model, the unmodified endogenous prostate cancer cell line, LNCaP, was used in this example. 177 For the evaluation of Lu-PSMA-ALB-056, we used PC-3 PIP, a transduced cell line that has much higher levels of PSMA expression than LNCaP cells. 27 Therefore, in previously reported studies 177 Lu-PSMA-ALB-056 and 177 The therapeutic doses of Lu-PSMA-617 (2 and 5 MBq) were lower than those used in this study (2.3 to 18.5 MBq). The second difference is the size of the tumors. 177 The mean tumor size used in the evaluation of Lu-PSMA-ALB-056 was approximately 100 mm 3 Whereas, 177 Lu-PSMA-617 or 177 In this study, the average tumor size when starting treatment with Lu-HTK01169 was 531-640 mm 3 The larger tumors in this example likely resulted in a greater degree of resistance to the treatment and subsequently required higher radiation doses to achieve similar growth inhibition.
[0096] 177 Compared to Lu-PSMA-617, albumin-binding agent was conjugated 177Lu-HTK01169 delivered 3.7-fold higher peak uptake and 8.3-fold higher total radiation dose to LNCaP tumor xenografts. Internal radiotherapy studies in mice bearing LNCaP cancer also demonstrated 177 Lu-HTK01169 achieved similar therapeutic efficacy with 177 This shows that only one-quarter of the administered radioactivity of Lu-PSMA-617 is required. 177 Lu or 225 HTK01169 radiolabeled with Ac 177 It has the potential to provide similar or improved radiotherapeutic efficacy at a fraction of the administered radioactivity of Lu-PSMA-617. The newly introduced albumin binder in HTK01169 can be directly assembled onto the solid phase along with the peptide extension. 177 Based on the encouraging data obtained from Lu-HTK01169, this new albumin binding motif has the potential to be applied to other (radioactive)peptides to extend blood retention time and maximize therapeutic efficacy.
[0097] Example 2: Modified metal chelating PSMA binding compounds 2.1 Materials and Methods 2.11 General method All chemicals and solvents were obtained from commercial sources and used without further purification. PSMA target peptides were synthesized using solid-phase methods on an Endeavor 90 peptide synthesizer from AAPPTec (Louisville, KY). Purification and quality control of cryo- and radiolabeled peptides were performed on an Agilent HPLC system equipped with a Model 1200 quaternary pump, a Model 1200 UV absorbance detector (set at 220 nm), and a Bioscan (Washington, DC) NaI scintillation detector. Operation of the Agilent HPLC system was controlled using Agilent ChemStation software. The HPLC columns used were a semi-preparative column (Luna C18, 5μ, 250 × 10 mm) and an analytical column (Luna C18, 5μ, 250 × 4.6 mm) purchased from Phenomenex (Torrance, CA). The collected HPLC eluate containing the desired peptide was lyophilized using a Labconco (Kansas City, MO) FreeZone 4.5 Plus freeze-dryer. Mass spectrometry was performed using an AB SCIEX (Framingham, MA) 4000 QTRAP mass spectrometer system equipped with an ESI ion source. C18 Sep-Pak cartridges (1 cm 3 , 50 mg) was obtained from Waters (Milford, MA). 68 Ga was eluted from an iThemba Labs (Somerset West, South Africa) generator and purified using a DGA resin column from Eichrom Technologies LLC (Lisle, IL). 68 The radioactivity of Ga-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC®-25R / W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies was counted using a Perkin Elmer (Waltham, MA) Wizard2 2480 automated gamma counter.
[0098] 2.12 Synthesis of HTK03026, HTK03027, HTK03029, and HTK03041 The structures of HTK03026, HTK03027, HTK03029, and HTK03041 are shown below: [ka]
[0099] Solid-phase syntheses of HTK3026, HTK03027, HTK03029, and HTK03041 were modified from literature procedures. 16 Fmoc-Lys(ivDde)-Wang resin (0.3 mmol, 0.61 mmol / g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 × 8 min). The isocyanate derivative of the di-t-butyl ester of glutamic acid (3 equiv.) was prepared according to literature procedures. 17 Lysine-immobilized resin was added and reacted for 16 hours. After washing the resin with DMF, the ivDde protecting group was removed with 2% hydrazine in DMF (5 x 5 min). Then, Fmoc-2-Aoc-OH (HTK03026), Fmoc-Ala(2-Anth)-OH (HTK03027), Fmoc-Ala(1-pyrenyl)-OH (HTK03029) or Fmoc-Ala(9-Anth)-OH (HTK03041) were coupled to the side chain of Lys using Fmoc-protected amino acid (3 eq.), HBTU (3 eq.), HOBT (3 eq.) and N,N-diisopropylethylamine (8 eq.). Then, Fmoc-tranexamic acid was added to continue the elongation, and finally DOTA-tris(t-bu) ester (2-(4,7,10-tris(2-(t-butoxy)-2-oxoethyl)-1,4,7,10)-tetraazacyclododecan-1-yl)acetic acid) was added.
[0100] The peptide was then deprotected and simultaneously cleaved from the resin by treatment with 95 / 5 trifluoroacetic acid (TFA) / triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by adding cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using a semi-preparative column. The eluate containing the desired peptide was collected, pooled, and lyophilized. The HPLC conditions for HTK03026 were 27% acetonitrile aqueous solution containing 0.1% TFA, and the flow rate was 4.5 mL / min. The retention time was 10.7 min. ESI-MS: calculated value [M+H] + (HTK03026) C 45 H 75 N9O 16 986.5; Measured value [M+H] + 986.6. The HPLC conditions for HTK03027 were 32% acetonitrile aqueous solution containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 7.1 min. ESI-MS: Calculated value [M+H] + (HTK03027) C 53 H 74 N9O 16 1092.5; Measured value [M+H] + 1094.6. The HPLC conditions for HTK03029 were 33% acetonitrile in water containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 7.3 min. ESI-MS: calculated value [M+H] + (HTK03029) C 55 H 74 N9O 16 1116.5; Measured value [M+H] + 1116.6. The HPLC conditions for HTK03041 were 31% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 7.2 min. ESI-MS: calculated value [M+H] + (HTK03041) C 53 H 74 N9O 16 1092.5; Measured value [M+H] + 1092.6.
[0101] 2.13 Synthesis of HTK03024, HTK03055, HTK03056, HTK03058, HTK03082, HTK03085, HTK03086, HTK03087, HTK03089, and HTK03090 The structures of HTK03024, HTK03055, HTK03056, HTK03058, HTK03085, HTK03086, HTK03087, HTK03089, and HTK03090 are shown below: [ka] where R = I (HTK03024), Cl (HTK03055), H (HTK03056), Br (HTK03058), F (HTK03085), OCH3 (HTK03086), NH2 (HTK03087), NO2 (HTK03089), or CH3 (HTK03090).
[0102] The structure of HTK03082 is shown below. [ka] (HTK03082) Fmoc-Lys(ivDde)-Wang resin (0.3 mmol, 0.61 mmol / g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 × 8 min). The isocyanate derivative of the di-t-butyl ester of glutamic acid (3 equiv.) was prepared according to literature procedures. 17Lysine-immobilized resin was added and reacted for 16 h. After washing the resin with DMF, the ivDde protecting group was removed with 2% hydrazine in DMF (5 × 5 min). Fmoc-2-Nal-OH was then coupled to the side chain of Lys by solid-phase peptide synthesis using Fmoc-based chemistry, followed by Fmoc-tranexamic acid, Fmoc-Lys(ivDde)-OH, and Fmoc-Gly-OH. All couplings were performed in DMF using Fmoc-protected amino acid (3 eq.), HBTU (3 eq.), HOBT (3 eq.), and DIEA (8 eq.). Elongation was then continued by coupling 4-(p-iodophenyl)butyric acid (for HTK03024), 4-(p-chlorophenyl)butyric acid (for HTK03055), 4-phenylbutyric acid (for HTK03056), 4-(p-bromophenyl)butyric acid (for HTK03058), 3-phenylpropanoic acid (for HTK03082), 4-(p-fluorophenyl)butyric acid (for HTK03085), 4-(p-methoxyphenyl)butyric acid (for HTK03086), 4-(p-(t-butyloxycarbonyl)aminophenyl)butyric acid (for HTK03087), 4-(p-nitrophenyl)butyric acid (for HTK03089), or 4-(p-tolyl)butyric acid (for HTK03090) to the same peptide-coupling resin using Fmoc-based chemistry. After selective removal of the ivDde protecting group with 2% hydrazine in DMF (5 × 5 min), the chelator DOTA was attached to the side chain of Lys to give the precursor.
[0103] The peptide was then deprotected and simultaneously cleaved from the resin by treatment with 95 / 5 trifluoroacetic acid (TFA) / triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by adding cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using a preparative column. The eluate containing the desired peptide was collected, pooled, and lyophilized. The HPLC conditions for HTK03024 were 37% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 8.8 min. ESI-MS: calculated value [M+H] + (HTK03024) C67 H 96 N 12 O 19 I 1499.6; Measured value [M+H] + 1499.6. The HPLC conditions for HTK03055 were 35% acetonitrile in water containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 9.7 min. ESI-MS: calculated value [M+H] + (HTK03055) C 67 H 96 N 12 O 19 Cl 1407.7; Found [M+H] + 1407.7. The HPLC conditions for HTK03056 were 0-80% acetonitrile aqueous solution containing 0.1% TFA (20 min) at a flow rate of 4.5 mL / min. The retention time was 13.4 min. ESI-MS: calculated value [M+H] + (HTK03056) C 67 H 97 N 12 O 19 1373.7; Measured value [M+H] + 1373.8. The HPLC conditions for HTK03058 were 0-80% acetonitrile in water containing 0.1% TFA (20 min) at a flow rate of 4.5 mL / min. The retention time was 13.4 min. ESI-MS: calculated value [M+H] + (HTK03058) C 67 H 96 N 12 O 19 Br 1451.6; Found value [M+H] + 1451.6. The HPLC conditions for HTK03082 were 31% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 11.1 min. ESI-MS: calculated value [M+H] + (HTK03082) C 66 H 95 N 12 O 19 1359.7; Measured value [M+H] + 1359.9. The HPLC conditions for HTK03085 were 34% acetonitrile in water containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 9.0 min. ESI-MS: calculated value [M+H] + (HTK03085) C 67 H 96 N 12 O 19 F 1391.7; Found value [M+H] + 1391.9. The HPLC conditions for HTK03086 were 33% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 9.1 min. ESI-MS: calculated value [M+H] + (HTK03086) C 68 H 99 N 12 O 20 1403.7; Measured value [M+H] + 1404.1. The HPLC conditions for HTK03087 were 23% acetonitrile aqueous solution containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 13.9 min. ESI-MS: calculated value [M+H] + (HTK03087) C 67 H 98 N 13 O 19 1388.7; Measured value [M+H] + 1389.0. The HPLC conditions for HTK03089 were 33% acetonitrile in water containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 10.6 min. ESI-MS: calculated value [M+H] + (HTK03089) C 67 H 96 N 13 O 21 1418.7; Measured value [M+H] + 1419.0. The HPLC conditions for HTK03090 were 35% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 9.1 min. ESI-MS: calculated value [M+H] + (HTK03090) C 68 H 99 N 12 O19 1387.7; Measured value [M+H] + 1387.9.
[0104] 2.14 Synthesis of Ga-labeled standards To prepare Ga-labeled standards, a solution of each precursor was incubated with GaCl3 (5 equiv.) in NaOAc buffer (0.1 M, 500 μL, pH 4.2) for 15 min at 80° C. The reaction mixture was then purified by HPLC using a preparative column, and the HPLC eluate containing the desired peptide was collected, pooled, and lyophilized. The HPLC conditions for Ga-HTK03026 were 27% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / L. The retention time was 9.4 min. ESI-MS: Calculated value [M+H] + (Ga-HTK03026) C 44 H 73 N9O 16 Ga 1052.4; Found value [M+H] + 1052.5. The HPLC conditions for Ga-HTK03027 were 32% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 9.5 min. ESI-MS: Calculated value [M+H] + (Ga-HTK03027) C 53 H 72 N9O 16 Ga 1159.4; Found value [M+H] + 1161.4. The HPLC conditions for HTK03029 were 33% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 10.3 min. ESI-MS: calculated value [M+H] + (Ga-HTK03029) C 55 H 72 N9O 16 Ga 1183.4; Found value [M+H] + 1183.4. The HPLC conditions for Ga-HTK03041 were 31% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / L. The retention time was 9.3 min. ESI-MS: Calculated value [M+H] +(Ga-HTK03041) C 53 H 72 N9O 16 Ga 1159.4; Found value [M+H] + 1159.4. The HPLC conditions for Ga-HTK03024 were 39% acetonitrile aqueous solution containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 8.0 min. ESI-MS: Calculated value [M+H] + (Ga-HTK03024) C 67 H 93 N 12 O 19 IGa 1565.5; Measured value [M+H] + 1565.5. The HPLC conditions for Ga-HTK03055 were 35% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / L. The retention time was 12.7 min. ESI-MS: calculated value [M+H] + (Ga-HTK03055) C 67 H 94 N 12 O 19 ClGa 1474.6; Found [M+H] 2+ 738.4. The HPLC conditions for Ga-HTK03056 were 34% acetonitrile aqueous solution containing 0.1% TFA at a flow rate of 4.5 mL / min. The retention time was 9.0 min. ESI-MS: Calculated value [M+H] + (Ga-HTK03056) C 67 H 94 N 12 O 19 Ga 1439.6; Found value [M+H] + 1439.8. The HPLC conditions for Ga-HTK03058 were 34% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 10.3 min. ESI-MS: calculated value [M+H] + (Ga-HTK03058) C 67 H 93 N 12 O 19 BrGa 1517.5; Found value [M+H] + 1518.0. The HPLC conditions for Ga-HTK03082 were 31% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 12.5 min. ESI-MS: calculated value [M+H] + (Ga-HTK03082) C 66 H 93 N 12 O 19 Ga 1426.6; Found value [M+H] + 1426.9. The HPLC conditions for Ga-HTK03085 were 34% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / L. The retention time was 9.0 min. ESI-MS: Calculated value [M+H] + (Ga-HTK03085) C 67 H 94 N 12 O 19 FGa 1458.6; Found value [M+H] + 1459.6. The HPLC conditions for Ga-HTK03086 were 33% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / min. The retention time was 12.0 min. ESI-MS: calculated value [M+H] + (Ga-HTK03089) C 67 H 94 N 13 O 21 Ga 1485.6; Found value [M+H] + 1485.9. The HPLC conditions for Ga-HTK03090 were 35% acetonitrile aqueous solution containing 0.1% TFA, with a flow rate of 4.5 mL / s. The retention time was 11.3 min. ESI-MS: calculated value [M+H] + (Ga-HTK03090) C 68 H 97 N 12 O 19 Ga 1454.6; Found value [M+H] + 1455.8.
[0105] 2.15 Cell culture The LNCaP cell line was obtained from ATCC (LNCaP clone FGC, CRL-1740). The cells were established from a metastatic site in the left supraclavicular lymph node of a human prostate adenocarcinoma. The cells were cultured in PRMI 1640 medium supplemented with 10% FBS, penicillin (100 U / mL), and streptomycin (100 μg / mL) at 37 °C in a humidified incubator containing 5% CO2. Cells grown to 80–90% confluence were then washed with sterile phosphate-buffered saline (1 × PBS pH 7.4) and trypsinized. The number of harvested cells was counted using a Hausser Scientific (Horsham, PA) hemocytometer.
[0106] 2.16 68 Synthesis of Ga-labeled compounds Purified in 0.5 mL of water 68 Ga was added to a 4 mL glass vial that had previously contained 0.7 mL of HEPES buffer (2 M, pH 5.0) and 50 μg of DOTA-containing precursor. The radiolabeling reaction was carried out under microwave heating for 1 min. The reaction mixture was purified by HPLC using the same semi-preparative column and conditions as described in section 2.14 for the purification of the respective non-radioactive Ga-labeled standards.
[0107] 2.17 PET / CT Imaging and Biodistribution Imaging and biodistribution studies were performed using NODSCID 1L2RγKO male mice. Mice were anesthetized with 2% isoflurane in oxygen and 1 × 10 7 LNCaP cells were implanted subcutaneously. Mice were imaged or used for biodistribution studies when tumors grew to 5–8 mm in diameter in 5–6 weeks.
[0108] PET imaging studies were performed using a Siemens Inveon microPET / CT scanner. Each tumor-bearing mouse was anesthetized (2% isoflurane in oxygen) with 6–8 MBq of CT imaging. 68Ga-labeled tracer was injected via the tail vein. Mice were allowed to recover and roam freely in their cages. After 50 min, mice were re-sedated with 2% isoflurane in inhaled oxygen and placed in the scanner. After segmentation to reconstruct PET images, a 10-min CT scan was first performed for localization and attenuation correction. Then, 10 min of static PET imaging was performed to measure uptake in the tumor and other organs. Between acquisitions, mice were kept warm on a heating pad. For contrast studies acquired 3 hours post-injection (pi), mice were placed in the microPET / CT scanner at 170 min pi. Then, CT scans were performed as described above, followed by 15 min of static PET imaging to measure uptake in the tumor and other organs.
[0109] For biodistribution studies, mice were injected with radiotracer as described above. At the designated time points (1 h or 3 h), mice were anesthetized with 2% isoflurane inhalation and euthanized with CO2 inhalation. Blood was collected immediately via the heart and organs / tissues of interest were harvested. Collected organs / tissues were weighed and counted using an automated gamma counter. Uptake in each organ / tissue was normalized to the injected dose using a standard curve and expressed as a percentage of the injected dose per gram of tissue (%ID / g).
[0110] 2.2 Results The results of this example are shown in Tables 7-10 and Figures 13-16. Combined with the results of Example 1, these results indicate that various compounds encompassed by Formula 1-a and Formula 1-b are particularly useful. [Table 7]
[0111] [Table 8]
[0112] U.S. Provisional Application No. 62 / 575,460, filed October 22, 2017, is incorporated herein by reference in its entirety. To the extent that there may be a conflict between a definition set forth in this application and a definition set forth in a document incorporated by reference, the definition in this application shall override the definition in the document incorporated by reference.
[0113] Although the invention has been described with respect to one or more embodiments, it will be apparent to those skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention, as defined in the claims.
[0114] [Table 9]
[0115] [Table 10]
[0116] Reference number (without inline notation of reference name) 1. Carter, RE; Feldman, AR; Coyle, JT Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 1996, 93, 749-753. 2. Silver, DA; Pellicer, I.; Fair, WR; Heston, WD; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3, 81-85. 3. Sokoloff, R. L.; Norton, K. C.; Gasior, C. L.; Marker, K. M.; Grauer, L. S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000, 43, 150-157. 4. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I trial of 177 lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 2005, 23, 4591-4601. 5. Afshar-Oromieh, A.; Haberkorn, U.; Zechmann, C.; Armor, T.; Mier, W.; Spohn, F.; Debus, N.; Holland-Letz, T.; Babich, J.; Kratochwil, C. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131 I-MIP-1095. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 950-959. 6. Heck, M. M.; Retz, M.; D’Alessandria, C.; Rauscher, I.; Scheidhauer, K.; Maurer, T.; Storz, E.; Janssen, F.; Schottelius, M.; Wester, H. J.; Gschwend, J. E.; Schwaiger, M.; Tauber, R.; Eiber, M. Systemic radioligand therapy with 177 Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J. Urol. 2016, 196, 382-391. 7. Kratochwil, C.; Giesel, F. L.; Stefanova, M.; Benesova, M.; Bronzel, M.; Afshar-Oromieh, A.; Mier, W.; Eder, M.; Kopka, K.; Haberkorn, U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177 Lu-labeled PSMA-617. J. Nucl. Med. 2016, 57, 1170-1176. 8. Rahbar, K.; Bode, A.; Weckesser, M.; Avramovic, N.; Claesener, M.; Stegger, L.; Bogemann, M. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin. Nucl. Med. 2016, 41, 522-528. 9. Fendler, W. P.; Reinhardt, S.; Ilhan, H.; Delker, A.; Boning, G.; Gildehaus, F. J.; Stief, C.; Bartenstein, P.; Gratzke, C.; Lehner, S.; Rominger, A. Preliminary experience with dosimetry, response and patient reported outcome after 177 Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 2017, 8, 3581-3590. 10. Rahbar, K.; Ahmadzadehfar, H.; Kratochwil, C.; Haberkorn, U.; Schafers, M.; Essler, M.; Baum, R. P.; Kulkarni, H. R.; Schmidt, M.; Drzezga, A.; Bartenstein, P.; Pfestroff, A.; Luster, M.; Lutzen, U.; Marx, M.; Prasad, V.; Brenner, W.; Heinzel, A.; Mottaghy, F. M.; Ruf, J.; Meyer, P. T.; Heuschkel, M.; Eveslage, M.; Bogemann, M.; Fendler, W. P.; Krause, B. J. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J. Nucl. Med. 2017, 58, 85-90. 11. Ahmadzadehfar, H.; Wegen, S.; Yordanova, A.; Fimmers, R.; Kurpig, S.; Eppard, E.; Wei, X.; Schlenkhoff, C.; Hauser, S.; Essler, M. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [ 177 Lu]Lu-PSMA-617. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1448-1454. 12. Brauer, A.; Grubert, L. S.; Roll, W.; Schrader, A. J.; Schafers, M.; Bogemann, M.; Rahbar, K. 177 Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1663-1670. 13. Yadav, M. P.; Ballal, S.; Tripathi, M.; Damle, N. A.; Sahoo, R. K.; Seth, A.; Bal, C. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 81-91. 14. Hofman, M. S.; Violet, J.; Hicks, R. J.; Ferdinandus, J.; Thang, S. P.; Akhurst, T.; Iravani, A.; Kong, G.; Kumar, A. R.; Murphy, D. G.; Eu, P.; Jackson, P.; Scalzo, M.; Williams, S. G.; Sandhu, S. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 825-833. 15. Kratochwil, C.; Bruchertseifer, F.; Giesel, F. L.; Weis, M.; Verburg, F. A.; Mottaghy, F.; Kopka, K.; Apostolidis, C.; Haberkorn, U.; Morgenstern, A. 225 Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 2016, 57, 1941-1944. 16. Benesova, M.; Schafer, M.; Bauder-Wust, U.; Afshar-Oromieh, A.; Kratochwil, C.; Mier, W.; Haberkorn, U.; Kopka, K.; Eder, M. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J. Nucl. Med. 2015, 56, 914-920. 17. Benesova, M.; Bauder-Wust, U.; Schafer, M.; Klika, K. D.; Mier, W.; Haberkorn, U.; Kopka, K.; Eder, M. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J. Med. Chem. 2016, 59, 1761-1775. 18. Kuo, H. T.; Pan, J.; Zhang, Z.; Lau, J.; Merkens, H.; Zhang, C.; Colpo, N.; Lin, K. S.; Benard, F. Effects of linker modification on tumor-to-kidney contrast of 68 Ga-labeled PSMA-targeted imaging probes. Mol. Pharmaceutics 2018, doi: 10.1021 / acs.molpharmaceut.8b00499 19. Meckel, M.; Kubicek, V.; Hermann, P.; Miederer, M.; Rosch, F. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting. Nucl. Med. Biol. 2016, 43, 670-678. 20. Harada, N.; Kimura, H.; Onoe, S.; Watanabe, H.; Matsuoka, D.; Arimitsu, K.; Ono, M,; Saji, H. Synthesis and biological evaluation of novel 18 F-labeled probes targeting prostate-specific membrane antigen for positron emission tomography of prostate cancer. J. Nucl. Med. 2016, 57, 1978-1984. 21. Chatalic, K. L. S.; Heskamp, S.; Konijnenberg, M.; Molkenboer-Kuenen, J. D. M.; Franssen, G. M.; Clahsen-van Groningen, M. C.; Schottelius, M.; Wester, H. J.; van Weerden, W. M.; Boerman, O. C.; de Jong, M. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics 2016, 6, 849-861. 22. Dumelin, C. E.; Trussel, S.; Buller, F.; Trachsel, E.; Bootz, F.; Zhang, Y.; Mannocci, L.; Beck, S.C.; Drumea-Mirancea, M.; Seeliger, M. W.; Baltes, C.; Muggler, T.; Kranz, F.; Rudin, M.; Melkko, S.; Scheuermann, J.; Neri, D. A portable albumin binder from a DNA-encoded chemical library. Angew. Chem. Int. Ed. 2008, 47, 3196-3201. 23. Muller, C.; Struthers, H.; Winiger, C.; Zhernosekov, K.; Schibli, R. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177 Lu-radionuclide tumor therapy in mice. J. Nucl. Med. 2013, 54, 124-131. 24. Choy, C. J.; Ling, X.; Geruntho, J. J.; Beyer, S. K.; Latoche, J. D.; Langton-Webster, B.; Anderson, C. J.; Berkman, C. E. 177 Lu-Labeled phosphoramidate-based PSMA inhibitors: The effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics 2017, 7, 1928-1939. 25. Kelly, J. M.; Amor-Coarasa, A.; Nikolopoulou, A.; Wustemann, T.; Barelli, P.; Kim, D.; Williams, C.; Zheng, X.; Bi, C.; Hu, B.; Warren, J. D.; Hage, D. S.; DiMagno, S. G.; Babich, J. W. Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer. J. Nucl. Med. 2017, 58, 1442-1449. 26. Benesova, M.; Umbricht, C. A.; Schibli, R.; Muller, C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol. Pharmaceutics 2018, 15, 934-946. 27. Umbricht, C. A.; Benesova, M.; Schibli, R.; Muller, C. Preclinical development of novel PSMA-targeting radioligands: Modulation of albumin-binding properties to improve prostate cancer therapy. Mol. Pharmaceutics 2018, 15, 2297-2306. 28. Kelly, J.; Amor-Coarasa, A.; Ponnala, S.; Nikolopoulou, A.; Williams, C.; Schlyer, D.; Zhao, Y.; Kim, D.; Babich, J. W. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur. J. Nucl. Med. Mol. Imaging 2018, doi: 10.1007 / s00259-018-4004-5. 29. Liu, Z.; Chen, X. Simple Bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 2016, 45, 1432-1456. 30. Apostolidis, C.; Molinet, R.; Rasmussen, G.; Morgenstern, A. Production of Ac-225 from Th-229 for targeted α therapy. Anal. Chem. 2005, 77, 6288-6291. 31. Walsh, K. M. Brookhaven National Laboratory: Radioisotopes for medical imaging and disease treatment. J. Nucl. Med. 2017, 58, 11N-12N. 37. Stabin MG, Sparks RB, Crowe E. OLINDA / EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. 38. Keenan MA, Stabin MG, Segars WP, Fernald MJ. RADAR realistic animal model series for dose assessment. J Nucl Med. 2010;51:471-476. 39. Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nucl Med. 2012;53:1807-1813. 40. Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41:149-160. 41. Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131 I-19-iodocholesterol: the pitfalls of using tissue concentration data. The author’s reply. J Nucl Med. 1975;16:248-249. 42. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med. 2004;45(10):1725-1733.
Claims
1. The following formula: [Formula 1] [In the formula, R is [chemical 2] is] A compound represented by the formula:
2. The compound of claim 1 having a radioactive metal bound thereto.
3. Radioactive metals, 64 Cu, 111 In, 89 Zr, 44 Sc, 68 G.A. 99m Tc, 86 Y. 152 Tb or 155 The compound of claim 2, wherein the compound is Tb.
4. The compound of claim 2, wherein the radiometal is 64Cu, 67Cu, 90Y, 111In, 114mIn, 117mSn, 153Sm, 149Tb, 161Tb, 177Lu, 225Ac, 213Bi, 224Ra, 212Bi, 212Pb, 225Ac, 227Th, 223Ra, 47Sc, 186Re or 188Re.
5. A composition comprising a compound according to any one of claims 1 to 4 and a pharma- ceutically acceptable excipient.
6. A composition comprising the compound of claim 3 and a pharma- ceutically acceptable excipient for imaging a prostate-specific membrane antigen (PSMA)-expressing cancer in a subject.
7. A composition comprising the compound of claim 4 and a pharma- ceutically acceptable excipient for treating a prostate-specific membrane antigen (PSMA)-expressing cancer in a subject.
8. 8. The composition of claim 6 or 7, wherein the cancer is prostate cancer, renal cancer, breast cancer, thyroid cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, lung cancer, liver cancer, brain cancer, melanoma, neuroendocrine tumor, ovarian cancer or sarcoma.
Citation Information
Patent Citations
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and agents for the treatment of prostate cancer
JP2016535013A
